MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan and to the deferral

MHRA-100024-PIP01-21-M02

Scope of the Application

Active Substance(s)

LAROTRECTINIB

Condition(s)

Malignant neoplasms (except CNS tumours, haematopoietic and lymphoid tissue neoplasms

Pharmaceutical Form(s)

Capsule, hard, Oral solution

Route(s) of Administration

Oral use, Gastric use

Name / Corporate name of the PIP applicant

Bayer plc

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Bayer plc submitted to the licensing authority on 28/09/2021 20:41 BST an application for a Modification

The procedure started on 18/01/2022 09:11 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100024-PIP01-21-M02

Of 09/02/2022 15:15 GMT

On the adopted decision for LAROTRECTINIB (MHRA-100024-PIP01-21-M02) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for LAROTRECTINIB, Capsule, hard, Oral solution , Oral use, Gastric use .

This decision is addressed to Bayer plc, 400, South Oak Way, Reading, United Kingdom, RG2 6AD

ANNEX I

1. Waiver

1.1 Condition:

Not applicable

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of all conditions included in the category of malignant neoplasms (except CNS tumours, haematopoietic and lymphoid tissue neoplasms)

2.2 Indication(s) targeted by the PIP:

Treatment of paediatric patients from birth to less than 18 years of age with advanced solid tumours harbouring an NTRK fusion

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

All subsets of the paediatric population from birth to less than 18 years of age

2.4 Pharmaceutical Form(s):

Capsule, hard; Oral solution

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	2	Study 1 Development of an oral solution (not containing ORA-SWEET) Study 2 Assessment of the administration of the oral solution (not containing ORA-SWEET) via a nasogastric tube
Non-Clinical Studies	2	Study 3 Dose range finding juvenile toxicity study in Sprague Dawley Rats Study 4 Juvenile toxicity study in Sprague Dawley Rats
Clinical Studies	1	Study 5 Open-label trial to evaluate the pharmacokinetics and safety of larotrectinib in paediatric patients with advanced solid or primary central nervous system tumours from birth to less than 18 years of age (and young adults of less than 22 years of age) (part 1-dose escalation) and to evaluate the anti-cancer activity of larotrectinib in an expansion cohort of paediatric patients from birth to less than 18 years of age (and young adults of less than 22 years of age) with tumours harbouring NTRK fusions (part 2). (LOXO-TRK-15003)
Extrapolation, Modeling & Simulation Studies	1	Study 6 Modelling and simulation study to evaluate the use and support dosing regimen of Larotrectinib in paediatric patients from birth to less than 18 years of age with tumours harbouring an NTK fusion (LOXO-101-DMPK-052).
Other Studies	0	Not applicable
Other Measures	0	Not applicable

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	31/10/2022
Deferral of one or more studies contained in the paediatric investigation plan:	Yes